Recent News

• 05.14.2026 - GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
• 04.08.2026 - GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
• 01.28.2026 - GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

Recent Filings

• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 8-K Current report
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.10.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2026 - 8-K Current report
• 02.04.2026 - EX-99.1 EX-99.1
• 01.30.2026 - S-3 Registration statement under Securities Act of 1933
• 01.30.2026 - 8-K Current report